Methylprednisolone hemisuccinateCAS# 2921-57-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2921-57-5 | SDF | Download SDF |
PubChem ID | 16923 | Appearance | Powder |
Formula | C26H34O8 | M.Wt | 474.5 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (210.73 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4-[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid | ||
SMILES | CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O | ||
Standard InChIKey | IMBXEJJVJRTNOW-XYMSELFBSA-N | ||
Standard InChI | InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Methylprednisolone hemisuccinate Dilution Calculator
Methylprednisolone hemisuccinate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1075 mL | 10.5374 mL | 21.0748 mL | 42.1496 mL | 52.687 mL |
5 mM | 0.4215 mL | 2.1075 mL | 4.215 mL | 8.4299 mL | 10.5374 mL |
10 mM | 0.2107 mL | 1.0537 mL | 2.1075 mL | 4.215 mL | 5.2687 mL |
50 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 0.843 mL | 1.0537 mL |
100 mM | 0.0211 mL | 0.1054 mL | 0.2107 mL | 0.4215 mL | 0.5269 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3',6'-Bis(diethylamino)-2-(4-nitrophenyl)spiro[isoindole-1,9'-xanthene]-3-one
Catalog No.:BCC8597
CAS No.:29199-09-5
- Shegansu B
Catalog No.:BCN3381
CAS No.:291535-65-4
- [Ala11,22,28]VIP
Catalog No.:BCC5754
CAS No.:291524-04-4
- 1-Methoxyberberine
Catalog No.:BCN7373
CAS No.:29133-52-6
- (+)-Affinisine
Catalog No.:BCN3520
CAS No.:2912-11-0
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- Guanfacine
Catalog No.:BCC5180
CAS No.:29110-47-2
- Procyanidin B2
Catalog No.:BCN6315
CAS No.:29106-49-8
- Pinoresinol dimethyl ether
Catalog No.:BCN6767
CAS No.:29106-36-3
- Glipizide
Catalog No.:BCC3785
CAS No.:29094-61-9
- Cimiracemoside D
Catalog No.:BCN2789
CAS No.:290821-39-5
- Avosentan
Catalog No.:BCC1387
CAS No.:290815-26-8
- Adenine HCl
Catalog No.:BCC4453
CAS No.:2922-28-3
- H-DL-Phe(4-NO2)-OH
Catalog No.:BCC3279
CAS No.:2922-40-9
- L-Kynurenine
Catalog No.:BCC3899
CAS No.:2922-83-0
- Dehydrotrametenolic acid
Catalog No.:BCN2718
CAS No.:29220-16-4
- SB-3CT
Catalog No.:BCC5486
CAS No.:292605-14-2
- 25,26-Dihydroxyvitamin D3
Catalog No.:BCC4201
CAS No.:29261-12-9
- L-685,458
Catalog No.:BCC2344
CAS No.:292632-98-5
- Deoxyelephantopin
Catalog No.:BCN4655
CAS No.:29307-03-7
- Genipin-1-O-gentiobioside
Catalog No.:BCN5349
CAS No.:29307-60-6
- Licarbazepine
Catalog No.:BCC7794
CAS No.:29331-92-8
- Tetrahydropalmatine
Catalog No.:BCN6310
CAS No.:2934-97-6
- Ciclopirox
Catalog No.:BCC4899
CAS No.:29342-05-0
Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy.[Pubmed:30529791]
Nanomedicine. 2019 Feb;16:34-44.
Glucocorticosteroids are the most efficacious anti-inflammatory agents and the gold standard treatment in Duchenne muscular dystrophy (DMD). However, their chronic use may lead to severe side effects. We evaluated the use of a novel injectable steroidal nano-drug in mdx mouse model of DMD by comparing the efficacy of nano-liposomes remotely loaded with the steroid prodrug, Methylprednisolone hemisuccinate (MPS) with the same steroid as-is, in short (4-weeks) and long-term (58-weeks) treatments. Liposomal-MPS was selectively targeted to the mouse diaphragm, the most dystrophic muscle at early stage of the disease. The bioactivity of the steroidal nano-drug was evidenced by a significant decreased serum TGF-beta and reduced diaphragm macrophage infiltration after short-term treatment. In the long-term, the treatment with liposomal-MPS not only demonstrated improved muscle strength and mobility it also induced lower tibia and lumbar vertebrae osteoporosis indicating much lower bone related adverse effects.